Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Infrastructure Sector Thematic Report - On the road to rerating - HDFC Securities

Posted On: 2020-09-13 23:53:06


Mr. Parikshit Kandpal, Institutional Research Analyst, HDFC Securities

Despite concerns around COVID-19, for the Infrastructure sector, this period has been mostly Reboot-2.0. (1) NHAI awarding (FYTD21) started with a bang (about to surpass FY20); (2) the largest client NHAI eased working capital for developers; (3) banks are using surplus liquidity and low interest rates to increase allocation to the sector; (4) concerns on NHAI balance sheet seem to be abating; (5) increase in fuel cess to add Rs 1tn to fund infra annually (total Rs 2.3tn); (6) asset monetisation to lead to BS deleveraging; and (7) Atmanirbhar and NIP programs' on-ground execution lends visibility to longer duration Indian Infra buildout. We remain optimistic and see sector rerating at a 4-5x book-to-bill and sub 6/4.6x P/E for FY22/23E when peak ordering is still some time away.

Multiple tailwinds to drive order book: The NHAI ordering in the last term of NDA government touched ~Rs 3.6tn (Rs 600bn/annum, FY14-19). Overall, road-related Capex annually has been Rs 2tn, and NIP envisages Rs 20tn of Capex in roads over the next five years (Rs 4tn annually). We believe this is a big ask though trend points to large Capex outlays. The NIP program may allay concerns on Bharatmala Phase 1 (BM-1) awards nearing completion and redrawing on BM-2 under NIP. This augurs well for more long-term ordering and sustainable sectoral growth.

Balance sheet improvement likely, FY23 to be the year of asset monetisation: We expect about 100+ HAM projects to achieve COD over the next two years. This has the potential to unlock about ~Rs 120bn of equity investments into the HAM projects by private developers. Even if we assume about 1.2x P/BV, the total investment is expected to be Rs 140bn ($2bn). With IRRs over 10%, the HAM INVIT may pose attractive risk-reward vs traditional savings instruments like FDs, AAA-rated bonds, Gsecs, etc. The monetisation may lead to further BS/CF improvement for our coverage universe.

Players diversifying order book given the risk of roads ordering saturation: Despite robust order pipeline and NIP program, developers understand the need to be diversification-ready over the next two years. DBL has already reduced roads exposure to 49.7% whilst KNR and Ashoka are at 60.3% and 80.3% respectively. PNC has bagged a small water project worth Rs 2.9bn and is looking to add more non roads projects over the next few quarters in water and railways/metro. Buildings segment players may not diversify, but given high entry barriers, robust government Capex pipeline on education and health sector, growth saturation is some time away. Even larger roads players are focusing on diversification more on the non-building segment.

The case for multiple rerating; 4 years infra awards runway ahead: FY21E awarding was supposed to be muted, post the COVID-19 pandemic, but we were positively surprised by robust awards. Horizontal developments like roads run across rural/urban areas and have considerable employment potential in rural areas. Besides, infrastructure creation is the backbone of manufacturing and translates to lower logistics costs. The plan resonates with the GOI Atmanirbhar schemes. The HAM assets, too, are backed by revenue models and decent IRRs. At sub 4.6x FY23E core P/E and peak awards some time away, we believe the sector has 1SD target P/E expansion potential of 2-3x PE from here. We have introduced FY23E financials for coverage companies and incorporated the P/E expansion changes in the detailed tables in the thematic section.

TOP PICKS: KNR, PNC Infra, Ashoka, Ahluwalia, Capacite Infra and KPTL.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

IPO Review - Computer Age Management Services - ICICI Securities

Company Update - EIH Ltd - ICICI Securities

Gladiator Stocks - Godrej Properties - ICICI Securities

Company Update - Dr Reddy's Laboratories - ICICI Securities

Gladiator Stocks: Pharma Thematic - ICICI Securities

Company Update - Housing & Urban Development - ICICI Securities

Covid Recovery Pulse - E-Way bill generation shows recovery signs with auto volumes flat - ICICI Securities

Quant Pick - UltraTech Cement - ICICI Securities

Lupin & Cipla - Positive News - Angel Broking

Sterling and Wilson Solar Ltd - 106.71 MW order win - Angel Broking

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Solar Industries - Overseas and defence key to profitability - ICICI Securities

Federal Bank - Strengthening liability muscle; fees & charges revised upwards - ICICI Securities

HCL Technologies Mr. Jyoti Roy, DVP - Equity Strategist, Angel Broking Ltd

CAMS - IPO Note - YES SECURITIES

I-direct Instinct - Intellect Design Arena

P&G Health - Company Update - ICICI Securities

Relaxo Footwears - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Bata India - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Listing of Happiest Minds Technologies - Angel Broking

Dr. Reddy's Lab - Sep 17, 2020 - Angel Broking

VA Tech Wabag - Uphill task ahead; dilution at discount valuation - ICICI Securities

Polymer price tracker - PVC price hikes continue unabated - ICICI Securities

Brigade Enterprises - Resilience amid turbulence - ICICI Securities

Apollo Hospitals Enterprises - Recovering well from COVID-19 impact - ICICI Securities

NTPC - Sustainability targets encouraging - ICICI Securities

Gladiator Stocks - Oberoi Realty - ICICI Securities

Gladiator Stocks - Automotive Axles - ICICI Securities

Quant Pick - IDFC First Bank - ICICI Securities

Company Update - Jammu & Kashmir Bank - ICICI Securities

India Aviation Data - August 2020 - Angel Broking

Shree Cement - Higher volumes to offset lower prices - ICICI Securities

Apollo Hospitals - Q1FY21 Result Update - ICICI Securities

Refining & marketing - Oil price fall boosted GRMs, to push marketing margins up - ICICI Securities

Mr. Deepak Jasani, Head of Retail Research views on FICCI National Executive Committee Meeting with Reserve Bank of India Governor Shaktikanta Das

India trade deficit for August 2020 - Angel Broking

Chemcon Chemicals IPO - Mr. Keshav Lahoti - Associate Equity Analyst, Angel Broking Ltd

CAMS IPO - Mr. Jaikishan Parmar - Sr. Equity Research Analyst, Angel Broking Ltd

August 2020 Trade Data - Acuité Ratings & Research

Wim Plast - Q1FY21 Result Update - ICICI Securities

Company Update - Mishra Dhatu Nigam - ICICI Securities

Stock Tales - Laurus Labs - ICICI Securities

Stock Tales - Granules India - ICICI Securities

Stock of the day - Chalet Hotel - Target INR 200 - Angel Broking

Upgrade to ADD on Dr. Reddy's Labs - Improved visibility in the US business - HDFC Securities

Monetary Policy post CPI inflation numbers for August 2020 - Angel Broking

HUDCO - Q1FY21 Result Update - Angel Broking

Update on Steriscience pharma - Angel Broking

Covid-19 vaccine development by AstraZeneca - Angel Broking







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019